Scarica l'app Stockscreener
2.29
0.88%
0.02
Dopo l'orario di chiusura:
2.34
0.05
+2.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$2.27
Aprire:
$2.21
Volume 24 ore:
32,108
Relative Volume:
0.35
Capitalizzazione di mercato:
$36.76M
Reddito:
$3.86M
Utile/perdita netta:
$-19.20M
Rapporto P/E:
-3.1465
EPS:
-0.7278
Flusso di cassa netto:
$-24.88M
1 W Prestazione:
+2.69%
1M Prestazione:
-12.60%
6M Prestazione:
-40.67%
1 anno Prestazione:
-63.93%
Intervallo 1D:
$2.21
$2.31
Intervallo di 1 settimana:
$2.06
$2.31
Portata 52W:
$2.06
$7.40
Veru Inc Stock (VERU) Company Profile
Nome
Veru Inc
Settore
Industria
Telefono
(312) 595-9123
Indirizzo
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.29 | 36.76M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-14 | Iniziato | B. Riley Securities | Buy |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2023-06-07 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-04-13 | Iniziato | Jefferies | Buy |
| 2021-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2018-07-03 | Iniziato | Maxim Group | Buy |
Mostra tutto
Veru Inc Borsa (VERU) Ultime notizie
Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial - MSN
MACD Signal: Is Veru Inc benefiting from innovation trendsWeekly Profit Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Veru SEC Filings - Stock Titan
Veru Q1 2026 earnings preview - MSN
Veru Inc. (VERU) Stock Price Quote Today & Current Price Chart - Capital.com
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
FRA:FMW0 PB Ratio: 1.74 — 41% Below Median - GuruFocus
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment - MSN
If You Invested $1,000 in Veru (VERU) - Stock Titan
Volume Recap: Is Veru Inc attractive for institutional investors2026 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Veru Inc. Amends 2018 Equity Incentive Plan and Reports Annual Meeting Results – Form 8-K Filing March 12, 2026 - Minichart
Veru Shareholders Expand Equity Plan, Reelect Board Leadership - TipRanks
Veru (NASDAQ: VERU) investors back larger equity plan, board slate and auditor - Stock Titan
Aug Macro: Is Veru Inc attractive for institutional investors2026 Opening Moves & Daily Market Momentum Tracking - baoquankhu1.vn
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study - TipRanks
Veru enrolls first patient in obesity drug combination trial By Investing.com - Investing.com Canada
Veru (VERU) Launches Phase 2b Trial for Obesity Treatment - GuruFocus
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TipRanks
Veru enrolls first patient in obesity drug combination trial - Investing.com Australia
Veru Inc. Initiates Phase 2b Clinical Trial for Enobosarm to Enhance Weight Loss in Older Patients with Obesity Receiving Semaglutide - Quiver Quantitative
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Yahoo Finance
VERU Earnings History & Surprises | EPS & Revenue Results | VERU INC (NASDAQ:VERU) - ChartMill
Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Veru : Corporate Presentation, February 2026 - marketscreener.com
VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VERU Should I Buy - Intellectia AI
Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com
VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI
Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI
Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
Veru Inc Azioni (VERU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):